























Chondroitin sulfate metabolism in the brain
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Over the last twenty years chondroitin sulfate (CS) has become a  focus of interest of neuroscience due to its indubitable role in 
shaping axonal growth, synaptic plasticity and glial scar forming. Various patterns of sulfation give rise to various CS molecules with 
different properties that are capable of interactions with a plethora of molecules, including growth factors, receptors and guidance 
molecules. The involvement of CS chains has been implicated in visual critical period regulation, memory formation, spinal cord 
regeneration. As part of proteoglycan molecules, they are widely expressed in the central nervous system, however, little is known 
about the enzymatic machinery responsible for CS synthesis and degradation. In this review we attempt to extract and collect the 
available information concerning the expression and function of enzymes of CS metabolism in the brain. 
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The extracellular matrix (ECM) of tissues is 
a non‑cellular structure, fundamentally composed of 
water, proteins and polysaccharides, occupying the 
space between cells, where the cells secrete these mol‑
ecules, thus determining the composition and proper‑
ties of ECM. 
ECM is a non‑cellular structure, fundamentally 
composed of water, proteins and polysaccharides. It 
occupies the intercellular space to which cells secrete 
various molecules, thus determining the composition 
and properties of ECM.
It is an important constituent of tissue microenvi‑
ronment, not only providing mechanical scaffold but 
also transporting ions and molecules, such as growth 
factors, chemokines and signaling molecules, affecting 
cell survival, migration and proliferation and regulat‑
ing tissue regeneration. It is thought to be crucial in 
development and aging. The number of pathological 
syndromes associated with abnormalities in ECM com‑
position implies ‑ its importance in proper functioning 
of tissues and organs (Järveläinen et al., 2009). Over the 
last decade, the brain ECM has drawn much attention. 
The role of ECM molecules has been demonstrated in 
brain development, critical period plasticity, adult neu‑
roplasticity and regenerative plasticity (Galtrey and 
Fawcett, 2007). Still, the mechanisms regulating syn‑
thesis and modification of brain ECM, as well as the way 
it regulates brain functioning, are far from understood. 
The brain ECM composition and function
Unlike in other tissues, the neural ECM is unique as 
to the content and architecture. Its striking feature is 
that it is almost devoid of fibrous proteins, instead it 
contains large amounts of polysaccharides, both un‑
bound and associated with proteins in the form of pro‑
teoglycans (Silbert and Sugumaran, 2002). The matrix 
of the brain occupies 20% of the brain volume (Sykova 
and Nicholson, 2008). Apart from water, which is the 
main component of most tissues, brain ECM contains 
large amounts of hyaluronic acid (HA), a long linear 
glycosaminoglycan composed of a repeating disaccha‑
ride unit of N‑acetylglucosamine (GlcNAc) and glucu‑
ronic acid (GlcA) (Csoka and Stern, 2013). The neural 
ECM also includes chondroitin sulfate proteoglycans 
(CSPGs) of the lectican family, which are characterized 
by the capability of interacting with HA. The CSPGs are 
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composed of a protein core that is decorated with chon‑
droitin sulfate (CS) chains attached through a covalent 
bond. CS is a glycosaminoglycan comprised of N‑acetyl‑
galactosamine (GalNAc) residues, alternating in ß(1‑3) 
and ß(1‑4) glycosidic linkages with glucuronic acid 
(GlcA). The GalNAc residues are diversely sulfated at 
the 4‑ and/or 6‑hydroxyl positions and, rarely, the GlcA 
residue can be sulfated at the 2‑ or 3‑hydroxyl positions 
(Couchman and Pataki, 2012). Unlike HA, CS chains do 
not occur in a free unbound form, but are covalently 
attached through a tetrasaccharide linker, to a serine 
residue in the protein core of CSPG. The CS chains vary 
in size up to a hundred or more disaccharide repeating 
units. Brain CSPGs of the lectican family are represent‑
ed by aggrecan, versican, neurocan and brevican (Ya‑
maguchi, 2000). The CSPG outside the lectican family is 
phosphacan ‑ a splice variant of receptor‑type protein 
tyrosine phosphatase (RPTP) that lacks the two intra‑
cellular tyrosine phosphatase domains that are found 
in RPTP (Maurel et al., 1994; Galtrey and Fawcett, 2007). 
Together with tenascins and link proteins of the HPLN 
(hyaluronan/HA and proteoglycan binding) family, HA 
and CSPGs form complex 3‑dimensional net‑like struc‑
tures around some neurons, mostly of the gamma‑am‑
inobutyric acid (GABA)ergic type (Celio and Blümcke, 
1994). The organization of CSPGs in these perineuronal 
nets (PNNs) during development coincides with critical 
period closure (Pizzorusso et al., 2002) and CSPGs, as 
a part of PNNs, have been implicated in limiting plas‑
ticity in adult animals (Gogolla et al., 2009; Balmer et 
al., 2009; Carulli et al., 2010; Slaker et al., 2015). A role 
for CSPGs in limiting cortical plasticity was confirmed 
in the studies using chondroitinase ABC (chABC), the 
enzyme capable of cleaving CS chains. Injection of 
chABC into the visual cortex reverses the effect of mon‑
ocular deprivation (Pizzorusso et al., 2006). Injected in 
superior colliculus, chABC enhances sprouting of reti‑
nal afferents after denervation of the superior collicu‑
lus resulting from a partial retinal lesion (Tropea et al., 
2003). These data support the notion that removal of 
CS chains from CSPGs molecules allows alterations in 
the neural circuitry and results in increased plasticity 
(Fox and Caterson, 2002). Moreover, it appears that the 
numbers of PNNs, while generally stable in adult brain, 
can be dramatically decreased upon ischemia, seizures 
and traumatic brain injury (Hobohm et al., 2005; Har‑
ris et al., 2010; Karetko‑Sysa et al., 2011; McRae et al., 
2012; Yi et al., 2012; Härtig et al., 2017). In view of the 
above mentioned data, this decrease can be considered 
as an attempt of the impaired brain to reinstate plas‑
ticity in order to allow axonal sprouting and compen‑
sation of damaged function (Carmichael et al., 2017). 
On the other hand, injuries to the central nervous sys‑
tem (CNS) result in upregulation of CSPGs in glial scar, 
which potently hinders neural plasticity and regenera‑
tion (McKeon et al., 1999; Beggah et al., 2005; Harris et 
al., 2009). For a comprehensive review of CS and CSPGs 
role in CNS plasticity see Bartus et al. (2012). CSPGs and 
PNNs have been also suggested to have neuroprotec‑
tive properties against oxidative stress (Morawski et 
al., 2004; Egea et al., 2010; Suttkus et al., 2012), the det‑
rimental effect of tau protein (Suttkus et al., 2016), or 
the effect of β‑amyloid (Miyata et al., 2007; Morawski et 
al., 2010; 2012). 
Despite growing evidence of the significance of 
CSPGs in the CNS, still little is known about CS metabo‑
lism in the neural tissue. CSPGs are widely distributed 
throughout the normal CNS, both during development 
and in the adulthood and are expressed mostly by neu‑
rons and astrocytes (Siebert et al., 2014). However, the 
molecular machinery responsible for their synthesis 
and degradation has not been well characterized. 
CS biosynthesis 
The synthesis of CS is a multistep, enzymatically 
regulated process, starting in the endoplasmic reticu‑
lum (ER) with the synthesis of the xylose (Xyl)‑galac‑
tose (Gal)‑galactose Gal)‑glucuronic acid (GlcA) linker 
from their UDP‑precursors (Fig. 1). The four glycosyl‑
transferases involved in the synthesis of the linkage 
region tetrasaccharide have been molecularly cloned 
(Mikami and Kitagawa, 2013). The process is initiated 
by the transfer of Xyl to the hydroxyl group of serine 
(Sugahara and Kitagawa, 2000). This step is catalyzed 
by xylosyltransferases, namely xylosyltransferase I and 
II (encoded by XYLT1 and XYLT2 genes, respectively) 
(Götting et al., 2000). The next step takes place in 
Golgi apparatus, where β1,4‑galactosyltransferase‑I 
(GalT‑I, encoded by B4GALT7 gene) adds the first Gal 
and β1,3‑galactosyltransferase‑II (GalT‑II, encoded by 
B3GALT6 gene) adds the second Gal molecule (Mikami 
and Kitagawa, 2013). The linker synthesis is completed 
with addition of GlcA in a reaction catalyzed by a glu‑
curonyltransferase GlcAT‑I, encoded by B3GAT3 gene 
(Kitagawa et al., 2001a). Additionally, the moieties com‑
prising the linker region can be modified. Transient 
phosphorylation of Xyl by xylose 2‑O‑kinase (coded for 
by FAM20B gene) has been described and this modifi‑
cation positively regulates the synthesis of the linker 
(Oegema et al., 1984; Lohmander et al., 1986; Gulberti 
et al., 2005; Tone et al., 2008; Koike et al., 2009). Further 
studies revealed that rapid dephosphorylation of Xyl 
by 2‑phosphoxylose phosphatase (encoded by PXYLP1 
gene) occurs at the stage of GlcA transfer to the linker, 
just before polymerization begins, and is indispens‑
able for CS polymerization (Koike et al., 2014). It has 
340 Gręda and Nowicka Acta Neurobiol Exp 2019, 79: 338–351
Fig. 1. Chondroitin sulfate biosynthesis pathway. 1: the formation of tetrasaccharide linker; 2: chondroitin chain polymerization and sulfation. The consecutive activi-
ties of xylosyltansferase(Xylt), β1,4‑galactosyltransferase (GalT‑I), β1,3‑galactosyltransferase (GalT‑II) and β1,3‑glucuronyltransferase (GlcAT‑I) lead to tetrasaccharide 
linker formation. Polimerization of the chondroitin chain is initiated by chondroitin GalNAc transferase I (GalNAcT‑I) activity and chondroitin chain elongation is 
catalyzed by chondroitin synthase complex, possesing both N‑acetylgalactosamine transferase II (GalNAcT‑II) and glucuronic acid transferase II (GlcAT‑II) activity, and 
comprised of chondroitin synthase (ChSy) and chondroitin polymerizing factor (ChPF). Nascent chondroitin chain is modified by sulfation catalyzed by sulfotrans-
ferases. An additional pathway of chondroitin polymerization may be executed through cooperation between ChGn‑1/2 and C4ST as N‑acetylgalactosamine trans-
ferase I/ II activity is facilitated by C4 sulfation of CS chain. (B3GALT6) β1,3‑galactosyltransferase 6; (B3GAT3) β1,3‑ glucuronyltransferase 3; (B4GALT7) β1,4‑galacto-
syltransferase 7; (C4ST) chondroitin 4‑O‑sulfotransferase; (C4ST1‑3) chondroitin 4‑O‑sulfotransferase 1‑3; (C6ST1/2) chondroitin 6‑O‑sulfotransferase 1/2; (ChGn‑1) 
chondroitin N‑acetylgalactosamine transferase; (CHPF) chondroitin polymerizing factor; (CHSY1‑3) chondroitin synthase 1‑3; (CS) chondroitin sulfate; (CSPG) chon-
droitin sulfate proteoglycan; (Gal) galactose; (GalNAc) N‑acetylgalactosamine; (GalNAc4s‑6ST) N‑acetylgalactosamine 4‑sulfate 6‑O‑sulfotransferase; (GalNAcT‑I/II) 
N‑acetylgalactosamine transferase I/II; (GalT‑I/II) galactosyltransferase I/II; (GlcA) glucuronic acid; (GlcAT‑I/II) glucuronic acid transferase I; (GlcAT‑S) glucuronic acid 
transferase S; (GlcAT‑P) glucuronic acid transferase P; (Ser) serine; (Xyl) xylose; (Xylt) xylosyltansferase; (XYLT1/2) xylosyltansferase 1/2). 
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been also reported that the sulfation at the C‑4 and/or 
C‑6 positions of Gal residues markedly influences Gal‑
NAcT‑I activity of ChGn‑1 and its catalytic efficiency 
(Kitagawa et al., 2008; Gulberti et al., 2012). 
The next phase of CS synthesis is chain elongation, 
starting with a transfer of a single GalNAc to the tet‑
rasaccharide linkage. This step is catalyzed by chon‑
droitin GalNAc transferase I (GalNAcT‑I). The first Gal‑
NAc transfer triggers the synthesis of the chondroitin 
backbone (Sugahara and Kitagawa, 2000; Silbert and 
Sugumaran, 2002). Since the linker region is common 
to both CS and heparan sulfate (HS), the activity of Gal‑
NAcT‑I seems to be crucial for differentiating between 
CS and HS synthesis. Further polymerization of chon‑
droitin proceeds with alternate additions of GlcA and 
GalNAc residues through the actions of GlcA transfer‑
ase II (GlcAT‑II) and GalNAc transferase II (GalNAcT‑II), 
respectively (Sugahara and Kitagawa, 2000; Silbert and 
Sugumaran, 2002). So far, six glycosyltransferases in‑
volved in chondroitin polymerization have been cloned 
in humans, namely ChGn‑1 (chondroitin GalNAc trans‑
ferase‑1, coded for by CSGALNACT1 gene) and ChGn‑2 
(CSGALNACT2), ChSy‑1 (chondroitin synthase‑1, CHSY1), 
ChSy‑2 (CHSY2), ChSy‑3 (CHSY3) and ChPF (chondroi‑
tin polymerizing factor, CHPF) (Kitagawa et al., 2001b; 
2003; Mikami and Kitagawa, 2013). 
ChSy‑1, ChSy‑2, and ChSy‑3, possess dual glycosyl‑
transferase activities, GlcAT‑II and GalNAcT‑II, howev‑
er, none of them can polymerize chondroitin, unless 
co‑expressed with CHPF (Kitagawa et al., 2001b; 2003; 
Izumikawa et al., 2007; 2008; Yada et al., 2003). The ac‑
tivity of the complex and the length of produced chon‑
droitin chain depend on the complex composition. In‑
terestingly, ChGn‑1 and ChGn‑2 reveal both GalNAcT‑I 
and GalNAcT‑II activity (Uyama et al., 2002; Gotoh et 
al., 2002a; 2002b; Sato et al., 2003; Uyama et al., 2003) 
probably serving as an additional machinery for con‑
trolling CS synthesis (for thorough review see Mikami 
and Kitagawa, 2013). 
In addition to heterogeneity resulting from various 
chain lengths, CS chains display considerable struc‑
tural variation due to diversified sulfation patterns. 
CS chains can be modified by sulfotransferases cat‑
alyzing the reaction of transfer of the sulfate group 
from 3′‑phosphoadenosine 5′‑phosphosulfate (PAPS) 
to specific sulfation sites on GalNAc or GlcA. Seven 
sulfotransferases involved in CS sulfation have been 
cloned so far. Six of them are GalNAc‑specific. These 
are chondroitin 4‑O‑sulfotransferase‑1, 2 and 3 (C4ST‑1 
‑ 3), transferring the sulfate group to the C‑4 location, 
chondroitin 6‑O‑sulfotransferase‑1, 2 (C6ST‑1 and 2) 
catalyzing 6‑O‑sulfation (Fukuta et.al. 1998; Hiraoka et 
al., 2000; Kitagawa et al., 2000; Yamauchi et al., 2000; 
Kang et al., 2002), and GalNAc 4‑sulfate 6‑O‑sulfotrans‑
ferase (GalNAc4S‑6ST), which transfers sulfate to the 
C‑6 position of the preexisting 4‑O‑sulfated GalNAc res‑
idue. The seventh sulfotransferase is uronyl 2‑O‑sulfo‑
transferase (UST), which occasionally sulfates GlcA in 
the C‑2 position of the preexisting 6‑O‑sulfated GalNAc. 
Based on the sulfation pattern, several CS disaccharide 
units have been distinguished: O‑unit (GlcA‑GalNAc), 
A unit (GlcA‑4SGalNAc), C unit (GlcA‑6SGalNAc), E 
unit (GlcA‑4S,6SGalNAc) and D unit (GlcA2S‑6SGalNAc) 
(Fig. 2). The role of GalNAc4S‑6ST is also suggested in 
CS synthesis termination, as the 4,6‑O‑disulfated Gal‑
NAc residue at the non‑reducing termini is 60‑fold 
more abundant than in interior disaccharides (Midura 
et al., 1995). 
CS and CSPGs expression in the brain 
Since the nervous tissue is recognized as contain‑
ing large amounts of CSPGs, CS synthesis is presumed 
to occur widely in most brain cells. Indeed, biochem‑
ical analysis of brain tissue homogenates subjected 
to chondroitinase treatment has revealed substantial 
amount of CS disaccharides of various types. The an‑
ion‑exchange high perfomance liquid chromatography 
(HPLC) analysis shows the predominance of A‑unit in 
adult mouse visual cortex (86.4%) over O‑unit (9%), 
C‑unit (2.7%) and E‑unit (1.24%) (Hou et al., 2017). Sim‑
ilar data came from the studies of Gilbert et al. (2005), 
where A‑unit accounted for 91% of the total CS amount, 
followed by O‑unit (5%) and C‑unit (4%), and those of 
Carulli et al. (2010) (91.5%, 3.5% and 2.5%, respectively). 
Various forms of ECM differ in their CS content, e.g. 
PNNs contain more CS‑C and CS‑E units and less CS‑A 
units than loose amorphous ECM (Deepa et al., 2006). 
Different brain regions express CS chains of different 
structure. A‑unit is a major component of CSPGs both 
in the cerebral cortex and cerebellum, however, the 
cerebellum is enriched in D‑unit, while the cerebral 
cortex contains a significant amount of E‑unit but little 
D‑unit (Maeda, 2010). 
The variety of CSPGs has been characterized in rat 
brain (Rauch et al., 1991; 1992; Jaworski et al., 1994; 
Gary et al., 2000; Milev et al., 1998; Matthews et al., 
2002). Because ECM CSPGs are localized extracellular‑
ly, it is not simple to establish the source of origin of 
specific CSPGs in the nervous tissue. Some answers 
come from in situ hybridization studies or from in vi‑
tro studies of primary neuronal or astrocytic cultures. 
In situ hybridization on the cerebellar sections from P3 
rats revealed the presence of brevican, neurocan, and 
phosphacan/RPTPbeta transcripts in glial cells, while 
at P21 brevican could also be found at low levels in 
some NeuN‑positive neurons (Carulli et al., 2006; 2007). 
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By combining in situ hybridization with immunostain‑
ing it was shown that neurocan‑expressing cells were 
Gfap‑positive and phosphacan/RPTPbeta transcripts 
were found neural/glial antigen 2 (NG2)–positive cells. 
In the adult cerebellum, neurocan was found only in 
neurons (Carulli et al., 2006). Contrastingly, the aggre‑
can mRNA was detected solely in neurons (Carulli et al., 
2006; 2007). Another CSPG of PNNs, versican, and more 
specifically its most abundant isoform V2, was local‑
ized to NG‑2‑positive cells (Carulli et al., 2007). These 
results were subsequently confirmed in in vitro studies, 
which showed astrocytic mRNA expression of brevican, 
neurocan, versican and phosphacan and neuronal ex‑
pression of aggrecan (Giamanco and Matthews, 2012). 
As virtually all types of cells in the brain are capable 
of expressing CSPGs, it is a justifiable assumption that 
all of them express the metabolic machinery involved 
in CS synthesis. Little is known, however, about the ex‑
pression and localization of particular enzymatic pro‑
teins in brain regions and cells. 
Linker synthesis enzymes in the brain 
Data concerning expression and localization of 
enzymes catalyzing the linker synthesis in the brain 
are particularly scarce. The activity of XylT enzyme 
is thought to be ubiquitous across organs and tissues. 
Both XYLTI and XYLTII were shown to be expressed in 
human brain at low levels (Götting et al., 2000; Condac 
et al., 2009) and in mouse brain (Pönighaus et al., 2007; 
Yin et al., 2009), as revealed with PCR method. Xylt1 and 
Xylt2 expression was reported in rat cortical astrocytes 
in primary cultures and Xylt‑1 immunoreactivity was 
Fig. 2. Chondroitin sulfate (CS) sulfation pathways. C4ST or C6ST activity catalyzes sulfation of chondroitin disaccharide unit. Addition of sulfate group at C4 or C6 
position of GalNAc initiates alternative CS chain modification pathways, which may be followed by GalNAc4S‑6ST or UST action, respectively. (C4ST) chondroitin 
4‑O‑sulfotransferase; chondroitin 6‑O‑sulfotransferase; (GalNAc) N‑acetylgalactosamine; (GlcA) glucuronic acid; (GalNAc4s‑6ST) N‑acetylgalactosamine 4‑sulfate 
6‑O‑sulfotransferase; (UST) uronyl 2‑O‑sulfotransferase).
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shown in the astrocytes of glial scar after spinal cord in‑
jury (Gris et al., 2007). B4GALT7 expression was reported 
in human brain using the northern blot method (Almei‑
da et al., 1999). RT‑PCR studies revealed the expression 
of B4galt7 in mouse cerebral cortex at postnatal day 1 
(P1) and in adult animals (8 weeks) (Yin et al., 2009). 
The brain expression of B3GALT6 mRNA was determined 
in human and mouse tissues by northern blot analysis 
(Zhou et al., 1999; Bai et al., 2001) and RT‑PCR (Yin et 
al., 2009). Another glycosytransferase involved in linker 
synthesis, GlcAT‑I, encoded by B3GAT3 gene, has been 
more often studied. The enzymatic activity was first 
purified from embryonic chick cartilage (Helting and 
Roden, 1969), and the native protein was partially pu‑
rified from embryonic chick brain (Brandt et al., 1969). 
The human gene was cloned (Kitagawa et al., 1998) and 
further studies using northern blot analysis revealed 
that it is abundantly expressed in brain (Kitagawa et al., 
2001b). Mouse B3gat3 (GlcAT‑I) gene expression in brain 
was also demonstrated, as early as at embryonic day 
7. Notably, in adult mouse brain, B3gat3 (GlcAT‑I) ex‑
pression was among the highest of all tissues examined 
(Wei et al., 1999; Kitagawa et al., 2001b; Yin et al., 2009). 
To our best knowledge, so far, no data have been pre‑
sented showing cellular or at least regional localization 
of B4galt7, B3galt6 and B3gat3 protein in animal brain. 
CS chain polymerization enzymes in the brain 
As mentioned above, Chgn‑1 and 2 are the enzymes 
having both GalNacT‑I and GalNacT‑II activity and 
therefore are thought to catalyze initiation and elonga‑
tion of the chondroitin chain. Despite similarity, the two 
enzymes apparently have different characteristics and 
co‑operate with different proteins to enhance CS syn‑
thesis. It has been shown that ChGn‑2 overexpression 
can positively regulate CS in co‑operation with C4ST‑1 
(Izumikawa et al., 2011) and ChGn‑1 more likely coop‑
erates with C4ST‑2 to increase the number of CS chains 
(Izumikawa et al., 2012). In human, both CSGALNACT1 
and CSGALNACT2 gene (ChGn‑1 and ChGn‑2 enzyme, 
respectively) expression was found across brain areas 
(Uyama et al., 2002; Sato et al., 2003). ChGn‑1 transcript 
presence has been also shown in mouse cerebral cor‑
tex (Yin et al., 2009). While virtually nothing is known 
about ChGn‑1 localization in particular cell types in the 
CNS, it appears that it can regulate the composition of 
PNNs. It was demonstrated in ChGn‑1 knockout mice 
that PNN presented diminished Cat‑316 epitope, sug‑
gesting that it was mainly synthesized in a ChGn‑1‑de‑
pendent manner. The molecular nature and biological 
role of this epitope hasn’t been identified yet, however, 
recent report showed that Cat‑316 antibody preferen‑
tially bound to CS chains rich in 4‑sulfated disaccharide 
unit (Yang et al., 2017). Cat‑316‑positive PNNs selective‑
ly bind Otx2, a molecule that is thought to be involved 
in parvalbumin‑positive interneuron maturation and 
induction of the critical period plasticity (Sugiyama 
et al., 2008; Miyata et al., 2018). Re cently, it has been 
shown that Otx2 binds to CSGALNACT1 promoter (Sakai 
et al., 2017). It appears then, that Otx2 may be directly 
involved in regulating the synthesis of CS chains (possi‑
bly of Cat‑316 type) which, in turn, are capable of bind‑
ing and accumulating Otx2. 
The main pathway of CS chain polymerization is 
mediated by the chondroitin synthase complex, con‑
sisting of any two of the four existing synthases, name‑
ly ChSy‑1, ChSy‑2, ChSy‑3 and CHPF but not of either 
one alone (Mikami and Kitagawa, 2013). Different com‑
binations result in different chain lengths, suggesting 
that the CS chain length is regulated depending on 
which synthase components are expressed in the cell. 
Although chondroitin synthases are indispensable for 
CS and CSPGs synthesis, for unexplainable reasons they 
have not drawn the attention they deserve. All mem‑
bers of the chondroitin synthase family are expressed 
in human brain (as visualized by northern blot analysis) 
(Izumikawa et al., 2008), however, no specific data are 
available concerning their cellular localization in the 
nervous tissue. We have come across one study showing 
ChSy1 expression in primary cultured microglia (Yin et 
al., 2009). In mouse brain, Chpf was demonstrated to 
be expressed in two splice variants, A and B, with the 
B isoform lacking an N‑terminal region of 162 amino 
acids present in A (Ogawa et al., 2010). In vitro studies 
demonstrated that both isoforms can form complexes 
with Chsy‑1 and with each other, however, in vitro gly‑
cosyltransferase assays reveal no polymerizing activity 
in ChpfB homodimer complexes and ChpfB/Chs‑1 com‑
plexes (Ogawa et al., 2010). The presence of Chpf pro‑
tein was demonstrated in Neu7 astrocyte cell line and 
in primary astrocytic cultures (Laabs et al., 2007). 
Chondroitin sulfation enzymes in the brain
To date, six sulfotransferases involved in CS bio‑
synthesis have been identified (Kusche‑Gullberg and 
Kjellén, 2003). The most typical modification in CS 
chain is 4‑O‑sulfation of GalNAc residues, mediated 
by chondroitin 4‑O‑sulfotransferases (C4st). Three of 
them have been cloned and characterized in mammals, 
namely C4st‑1, C4st‑2 and C4st‑3 (Yamauchi et al., 
2000; Hiraoka et al., 2000; Kang et al., 2002). The first 
two enzymes are broadly expressed. C4st‑1 protein/
activity was first isolated from the culture medium of 
rat chondrosarcoma cells (Yamauchi et al., 1999), then 
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the mouse ortholog was cloned from the brain tissue. 
Northern analysis indicated that, among various tis‑
sues tested, C4st1 expression was most abundant in 
mouse brain and kidney (Yamauchi et al., 2000). Hu‑
man C4ST1 and C4ST2 were subsequently cloned and 
their expression was demonstrated in most brain ar‑
eas, with highest expression of C4ST1 in the caudate 
nucleus, putamen, amygdala and spinal cord, and 
lower levels in the cortex. C4ST2 expression was most 
prominent in the spinal cord, cerebellum, substantia 
nigra and thalamus and lower levels were found in cor‑
tical areas (Hiraoka et al., 2000). The last member of 
the family, C4ST3, presented a more restricted pattern 
of expression in human tissues. The transcript was 
found in the liver and kidney and, surprisingly, low 
level of expression could also be observed in paracen‑
tral gyrus of cerebral cortex (Kang et al., 2002) sug‑
gesting that C4ST3 expression might still be present in 
some restricted brain areas. C4st1 and C4st2 expression 
was demonstrated in astrocyte cell cultures and C4st1 
protein was also detected (Properzi et al., 2005; Wang 
et al., 2008; Yamauchi et al., 2011; Bhattacharyya et al., 
2015). Among other sulfotransferases, C4st1 expression 
was also observed in neurogenic niches of developing 
and adult mouse brain, as revealed by in situ hybridiza‑
tion (Akita et al., 2008) and in neuronal cultures (Yam‑
auchi et al., 2011). Other in situ hybridization studies 
showed strong C4st1 expression in the olfactory bulb, 
striatum, hippocampus and cortex (Sugahara and Mi‑
kami, 2007). Although C4st1 and C4st2 pattern of ex‑
pression is to some extent overlapping, it seems that 
their roles in CS synthesis are not interchangeable. 
Experimental knockout of C4st1 results in drastic loss 
not only in 4‑O‑sulfation, but also in the amount of CS 
synthesis (Izumikawa et al., 2011). This suggests that 
the lack of C4ST‑1 activity cannot be compensated by 
other sulfotransferases and that C4ST‑1 plays a crucial 
role not only in 4‑O sulfation but also in regulation of 
CS biosynthesis (Izumikawa et al., 2011). 
Another sulfotransferase involved in CS sulfation, 
namely chondroitin 6‑O‑sulfotransferase (C6ST), trans‑
fers the sulfate group to the C‑6 position of GalNac resi‑
due and its activity results in C‑unit formation. To date, 
two isoforms C6ST‑1 and C6ST‑2 encoded by separate 
genes (C6ST1 and C6ST2) were cloned in humans and 
mice (Fukuta et al., 1998; Mazany et al., 1998; Uchimura 
et al., 1998; Kitagawa et al., 2000). C6ST1 expression was 
first demonstrated in brain by northern blot analysis 
(Fukuta et al., 1998). Likewise, the same method re‑
vealed broad expression of C6ST2 mRNA in many brain 
areas, with highest levels in the frontal and occipital 
lobes of cerebral cortex (Kitagawa et al., 2000). In mice, 
the C6st1 ortholog was cloned (Uchimura et al., 2002). 
Knockout studies proved that that 6‑O sulfation was 
compromised in the brain of these animals and C‑units 
decreased by 90% in the brain tissue extracts, similarly 
to D‑units. However, roughly normal brain organiza‑
tion and cortical pyramidal neuron processes were ob‑
served (Uchimura et al., 2002). Interestingly, transgenic 
mice overexpressing C6st‑1 present enhanced and pro‑
longed plasticity in the visual cortex pointing to the 
possibility of plasticity regulation by the C4/C6 ratio 
(Miyata et al., 2012). Limited data that are available on 
C6ST‑1 expression in CNS suggest widespread localiza‑
tion of enzyme protein in the neural tissue cells. Yin 
et al. (2009) reported C6ST1 expression in transforming 
growth factor (TGF)‑β‑acivated microglial primary cul‑
tures. Low levels of C6st1 expression were found in neu‑
ronal and astrocytic in vitro cultures (Yamauchi et al., 
2011) and in oligodendrocyte precursor cells and endo‑
thelial cells in injured cerebral cortex (Properzi et al., 
2005). C6st1 mRNA expression is developmentally regu‑
lated and is much higher at E18 than at P0 and in adult 
animals (Properzi et al., 2005). Increased C6st‑1 immu‑
noreactivity in astrocytes was observed in stab‑injured 
cortex (Okuda et al., 2014). As to C6st‑2, its specific lo‑
calization to cells of the nervous tissue remains to be 
clearly determined. 
GalNAc 4‑sulfate 6‑O‑sulfotransferase (GalNAc4S‑6ST), 
a sulfotransferase transferring the sulfate group to the 
C‑6 position in A‑unit is thus responsible for the syn‑
thesis of E‑unit of CS chains. It was first cloned from hu‑
man tissue, based on the squid cartilage enzyme amino 
acid sequence (Ohtake et al., 2001). While no thorough 
expression analysis was performed for the cloned se‑
quence, it is clear that CNS contains substantial amounts 
of E‑unit‑containing CS chains that play a crucial role in 
regulating axonal growth and neuronal plasticity (Gal‑
trey and Fawcett, 2007). As knockout animals lacking 
GalNAc4S‑6ST expression cannot produce CS contain‑
ing 4,6‑O‑disulfated GalNAc residues, it seems that Gal‑
NAc4S‑6ST is the sole enzyme responsible for this mod‑
ification (Ohtake‑Niimi et al., 2010). This leads to a con‑
clusion that this enzyme is undoubtedly expressed in the 
CNS. Later in situ hybridization studies documented Gal‑
NAc4S6ST expression during mouse brain development, 
with ubiquitous expression at P14 and more restricted 
in adult animals, within olfactory bulb, striatum, cere‑
bellum, dentate gyrus and cerebral cortical layers (Pu‑
rushothaman et al., 2007). More detailed studies in de‑
veloping cerebellum showed GalNAc4S6ST expression 
in Purkinje cells, granule neurons, small inhibitory 
neurons and Golgi neurons (Ishii and Maeda 2008). The 
GalNAc4S6ST expression was also indicated in astrocytic 
brain tumors (Kobayashi et al., 2013). 
Uronyl 2‑O‑sulfotransferase (UST) catalyzes 2‑O‑sul‑
fation of the GlcA residue in C unit of CS chains. This 
modification does occur in CS chains, it is, however, less 
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frequent (Hou et al., 2016). Human UST is expressed in 
brain (Kobayashi et al., 1999). In mouse brain, Ust ex‑
pression was confirmed by RT PCR and in situ hybrid‑
ization in cells localized in the ventricular zones of the 
ventral and dorsal telencephalon and in cultured neu‑
rospheres (Akita et al., 2008), as well as in differentiated 
cultured neural cells (Yamauchi et al., 2011). It is down‑
regulated during development and its expression drops 
significantly between E18 and P0 (Properzi et al., 2005). 
To date, no published data exist concerning possible 
significance of CS 2‑O sulfation in the nervous tissue. In 
non‑neuronal cells, UST knockdown resulted in inhibi‑
tion of cell migration (Nikolovska et al., 2015). 
CS catabolism 
The processes that contribute to CS catabolism are 
not well understood. However, provided that CS chains 
are indeed digested by enzymes originally assigned to 
HA degradation, paradoxically some information can 
be drawn from HA metabolism studies. The CS degra‑
dation is thought to predominantly occur in lysosomes 
(Prabhakar and Sasisekharan, 2006). CS degradation 
begins with desulfation of the backbone chondroitin 
chain by lysosomal sulfatases, arylsulfatase B (coded 
for by ARSB gene) and N‑acetylgalactosamine‑6‑sul‑
fatase (coded for by GALNS gene), which remove the 
sulfate group at the C‑4 position and the C‑6 position, 
respectively (Ingmar and Wasteson, 1979; Glössl et al., 
1979; Bhattacharyya et al., 2009a). On the basis of simi‑
larity of chondroitin backbone with HA, it is presumed, 
that bare chondroitin chains are degraded in lysosomes 
by some endoglycosidases and the digestion is contin‑
ued by exoglycosidases acting at the non‑reducing end 
of the polysaccharide. However, no specific enzymes 
have been attributed to these processes. It has been re‑
ported, however, that some of hyaluronidases, namely 
HYAL‑1, HYAL‑4, and SPAM1 (testicular hyaluronidase, 
PH‑20) have CS‑degrading activities (Csoka et al., 2001; 
Jedrzejas and Stern, 2005). It has been shown in in vi‑
tro studies that HYAL‑1 depolymerize CS‑A and HA to 
a similar extent and SPAM1 degrade CS‑A, chondroitin, 
and HA to a similar extent (Csoka et al., 2001; Jedrzejas 
and Stern, 2005; Honda et al., 2012). 
HYAL‑4 reveals hydrolytic activity towards CS, how‑
ever, its expression is restricted to few organs so it can‑
not be considered responsible for systemic CS catabo‑
lism (Kaneiwa et al., 2010; 2012). Further degradation is 
possibly mediated by ß‑hexosaminidase and ß‑glucuro‑
nidase, the two exoglycosidases that are also responsi‑
ble for the degradation of HA. Indeed, double knockout 
mice lacking ß‑hexosaminidase activity accumulate ex‑
cessive CS (Gushulak et al., 2012). 
CS catabolism enzymes in the brain 
As mentioned above, the CS degradation pathway is 
poorly recognized and this is true also for the brain. 
The first step of CS degradation, exclusive for CS and 
not shared with HA, is desulfation, followed by deg‑
radation of desulfated chondroitin backbone with hy‑
aluronidases and exoglycosidases. Desulfation is cat‑
alyzed by sulfatases, namely N‑acetylgalactosamine 
4‑sulfatase (arylsulfatase B, ARSB) and N‑acetylgalac‑
tosamine 6‑sulfatase (GALNS). Interestingly, recent 
studies demonstrated that ARSB is not just a lysosomal 
enzyme but can also be present at the cell membrane 
(Bhattacharyya et al., 2009a; 2009b; Mitsunaga‑Nakat‑
subo et al., 2009; Prabhu et al., 2011). ARSB activity and 
expression was demonstrated in brain and its activity 
decreased in the ipsilateral hemisphere after unilater‑
al injury (Bhattacharyya et al., 2015). ARSB mRNA was 
also detected in astrocytic cultures (Zhang et al., 2014; 
Bhattacharyya et al., 2015). GALNS presence in brain is 
poorly documented. Enzymatic activity was detected in 
brain extracts (Motas et al., 2016) and in rat primary 
astrocyte cultures (Zhang et al., 2014). 
Once desulfated, the chondroitin backbone is sub‑
jected to further degradation by hyaluronidases. Hyal‑1 
has been proved to have catabolic activity towards CS 
chains (Honda et al., 2012). While it is thought to be the 
main hyaluronidase in all tissues (Csoka et al., 2001), 
when first cloned in humans, its expression could not 
be confirmed in brain (Frost et al., 1997). Low levels of 
Hyal1 expression were found in mouse brain (Shuttle‑
worth et al., 2002). Later studies, however, demonstrat‑
ed Hyal1/HYAL1 expression in brain extracts (Al’Qteishat 
et al., 2006a; 2006b; Xing et al., 2014). HYAL‑1 immuno‑
reactivity in stroke patients’ brains was found in per‑
ilesional and ischemic tissue, mostly in neurons and 
oligodendrocytes, but not in astrocytes (Al’Qteishat 
et al., 2006b). Contrastingly, Hyal‑1 immunoreactivity 
was found in astrocytes of rostral migratory stream and 
subventricular zone in mice and in perilesional cortex 
of stroke animals (Lindwall et al., 2013). 
Hyal‑4 is the only CS‑specific endo‑type hydro‑
lase identified to date, however, its role in CS degra‑
dation has not been thoroughly investigated. Human 
and mouse orthologs differ substantially in their sub‑
strate specificities: human HYAL‑4 strongly prefers 
D‑unit‑rich CS, while mouse enzyme depolymerized 
A‑ C‑ and D‑rich CS to a similar extent (Kaneiwa et al., 
2012). Hyal‑4 expression in brain has not been proved 
so far. Early studies reported HYAL4 expression re‑
stricted to placenta and skeletal muscle (Csoka et al., 
1999). However, Xing et al. (2014) reported low levels 
of Hyal4 in rat cerebral cortex of control and injured 
brain, detected with RT‑PCR. Moreover, Hyal‑4 protein 
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expression was documented in spinal cord, after spi‑
nal cord transection (Tachi et al., 2015). The enzyme 
was found in activated fibrous astrocytes of glial scar. 
These results suggest that, at least under pathological 
conditions, the cells of the nervous tissue do have the 
capability of Hyal‑4 expression. 
Another hyaluronidase possibly involved in CS 
degradation is PH‑20 encoded by SPAM1 gene (Lin et 
al., 1993; Jones et al., 1995). Both these early studies 
showed PH‑20 expression strictly limited to testes. 
However, Sloane and co‑workers found that oligoden‑
drocyte precursor cells (OPCs) expressed PH‑20, as con‑
firmed by immunocytochemistry (Sloane et al., 2010). 
Subsequent studies confirmed astrocytic and OPCs 
PH‑20 expression in vitro and in vivo by immunofluo‑
rescence, and transcript presence was revealed by PCR 
(Preston et al., 2013). PH20 mRNA was also confirmed 
in rat brain (Xing et al., 2014). Finally, PH‑20 transcript 
was found detected using nested PCR method and as‑
trocytic PH‑20 immunoreactivity was confirmed in 
ischemically injured white matter in sheep (Hagen et 
al., 2014). These results were, however, questioned by 
Marella et al. (2017), who endeavored to replicate the 
results of Preston et al., and Hagen et al., and claimed 
lack of PH‑20 expression in OPCs cultures in vitro and 
in the CNS. Clearly, the matter of PH‑20 expression and 
its role in CS (and HA, obviously) degradation in brain 
requires further extensive investigation. 
As hyaluronidases cleave HA/CS to mostly tetra‑
saccharides, the last step liberating single monosug‑
ar moieties is probably mediated by exoglycosidases. 
These are ß‑glucuronidase (encoded by GUSB gene) and 
ß‑hexosaminidase (a dimer o two subunits encoded by 
HEXA and HEXB genes), which sequentially cleave gly‑
cosaminoglycans at a non‑reducing end of the chain. 
The two lysosomal enzymes haven’t appealed much to 
neuroscientists and the number of reports concerning 
their brain expression or activity is not impressive. Few 
studies have shown the presence of ß‑glucuronidase en‑
zymatic activity in neural cells. It was detected in hip‑
pocampal pyramidal neurons and in granule neurons 
in the cerebellum, and also in granule neurons of the 
dentate gyrus. ß‑glucuronidase localized to perikary‑
ons and dendrites. After brain injury, ß‑glucuronidase 
activity appeared also in glial cells (Vijayan and Cotman 
1983). Microglial localization of ß‑glucuronidase was re‑
ported in the hypoplastic cerebellum of jaundiced Gunn 
rats (Keino et al., 1990). The activity was also discovered 
in astrocyte cultures in vitro, however, it was restricted 
to some cells (Kroh and Renkawek, 1973). Gusb mRNA 
expression was found in mouse brain, however at sub‑
stantially lower levels than in other tissues (Bracey and 
Paigen, 1987). Gusb protein was detected in brain ex‑
tracts from rat and monkey (Robins et al., 1968). 
Hex genes have been hardly investigated regarding 
their brain expression. It is disappointing, considering 
their metabolic implications. Genetic mutation in HEXA 
gene results in ß‑hexosaminidase inactivity and causes 
Tay‑Sachs disease, a lethal syndrome including severe 
neurological dysfunctions and pathological accumula‑
tion of metabolites in neurons. In turn, HEXB mutations 
cause Sandhoff disease, resulting in massive accumula‑
tion of GM2 ganglioside in CNS (Cordeiro et al., 2000). 
Hexa expression in mice was assessed by northern blot, 
which revealed the presence of Hexa mRNA at substan‑
tial levels in brain (Wakamatsu et al., 1994) and Hexb ex‑
pression has been shown to be upregulated after MCAO 
(Tao et al., 2015). Triple knockouts Hyal1‑/‑/Hexa‑/‑/
Hexb‑/‑, resulting in mice deficient in both Hyal1 and 
ß‑hexosaminidase, accumulated substantial amounts 
of non‑sulfated chondroitin in brain (Gushulak et al., 
2012). While chondroitin normally is not expressed in 
brain, it is conceivable that the chondroitin found in 
the triple knockout tissues may be derived from inter‑
mediates of CS metabolism that have already been de‑
sulfated by sulfatases (Gushulak et al., 2012). 
CS metabolism in brain pathology 
It is widely accepted that CSPGs, and their CS chains 
in particular, are main inhibitory molecules in the CNS 
limiting neural plasticity. In healthy adult brain, the 
ECM is rather stable, comprised of large amounts of in‑
hibitory CS‑A unit‑bearing CSPGs, which make the ex‑
tracellular space suppressive for the growing processes 
(Maeda, 2010). However, upon various pathological con‑
ditions the structure of ECM changes dramatically in 
order to create a more plasticity‑friendly environment 
(Hobohm et al., 2005; Karetko‑Sysa et al., 2011; McRae et 
al., 2012; Härtig et al., 2017). On the other hand, during 
glial scar formation, upregulation of inhibitory CSPGs 
occurs, preventing axonal growth and regeneration 
(Kleene and Schachner, 2004) Digestion of CS chains 
with chABC improves axon regeneration and function‑
al recovery (Bradbury et al., 2002). It appears that the 
composition of CS chains is regulated upon brain injury. 
Increased CS‑C immunoreactivity was observed around 
the stab wound injury in cerebral cortex (Properzi et al., 
2005; Okuda et al., 2014) and the increase was accompa‑
nied with the increase in C6st1 expression (Properzi et 
al., 2005). The content of CS‑C and CS‑E units dramati‑
cally increased in injured cortex, and CS‑A units were 
downregulated (Gilbert et al., 2005). In injured spinal 
cord, CS‑A unit content rapidly increases in areas that 
do not support axonal regeneration (Wang et al., 2008). 
Similarly, in TBI cortex, an increase in CS‑A content, 
as well as increased immunoreactivity of CS‑A was ob‑
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served in pericontusional tissue (Yi et al., 12). Interest‑
ingly, other studies showed that Arsb activity is down‑
regulated and C4st‑1 upregulated upon cortical injury 
(Bhattacharyya et al., 2015) implying the role of the two 
enzymes in regulating CS‑A content and C4/C6 sulfation 
ratio. The significance of changes in the C4/C6 sulfation 
ratio in injured brain is still not quite clear. Whereas 
CS‑A unit‑rich CS chains are widely accepted to be in‑
hibitory (Wang et al., 2008; Yi et al., 2012; Siebert et al., 
2014), there is controversy about CS‑C properties as 
some groups reported it as inhibitory for axonal growth 
(Snow et al., 1990) while others claim it as permissive 
(Lin et al., 2011). Similarly, there is no consensus on 
whether CS‑E enhances or impedes neurite outgrowth, 
it is most often, however, considered inhibitory (Gilbert 
et al., 2005; Miyata and Kitagawa 2017). 
CONCLUSION 
There is growing amount of evidence that CS chains 
of brain ECM play an important role in limitation of neu‑
ronal plasticity and nervous tissue regeneration after 
injuries. Chondroitinase ABC studies proved that mod‑
ification of CS expression in the tissue is a reasonable 
approach to facilitating tissue repair. The CS content in 
brain is changing during development and in pathologi‑
cal conditions and clearly is a subject of enzymatic con‑
trol. Despite this, remarkably little is known about the 
regulation of CS synthesis and degradation in the brain. 
The knowledge concerning enzymes of CS metabolism 
is scarce and scattered and there are questions that 
still need answers. What is their localization to specific 
brain structures and cell types? How is their expression 
and activity regulated? Considering the enzymatic ma‑
chinery of CS metabolism a promising target to manipu‑
late, these questions need to be touched upon. 
ACKNOWLEDGEMENTS 
This work was supported by Polish National Sci‑
ence Center grants no. 2012/05/B/NZ3/00851 and 
2015/17/N/NZ3/02244. 
REFERENCES
Akita K, von Holst A, Furukawa Y, Mikami T, Sugahara K, Faissner A (2008) 
Expression of multiple chondroitin/dermatan sulfotransferases in the 
neurogenic regions of the embryonic and adult central nervous system 
implies that complex chondroitin sulfates have a role in neural stem cell 
maintenance. Stem Cells 26: 798–809. 
Almeida R, Levery SB, Mandel U, Kresse H, Schwientek T, Bennett EP, 
Clausen H (1999) Cloning and expression of a proteoglycan UDP‑galac-
tose: beta‑xylose beta1,4‑galactosyltransferase I. A seventh member of 
the human beta4‑galactosyltransferase gene family. J  Biol Chem 274: 
26165–26171. 
Al Qteishat A, Gaffney JJ, Krupinski J, Slevin M (2006a) Hyaluronan expres-
sion following middle cerebral artery occlusion in the rat. Neuroreport 
17: 1111–1114. 
Al’Qteishat A, Gaffney J, Krupinski J, Rubio F, West D, Kumar S, Kumar P, 
Mitsios N, Slevin M (2006b) Changes in hyaluronan production and 
metabolism following ischaemic stroke in man. Brain 129: 2158–2176. 
Bai X, Zhou D, Brown JR, Crawford BE, Hennet T, Esko JD (2001) Biosyn-
thesis of the linkage region of glycosaminoglycans: cloning and activity 
of galactosyltransferase II, the sixth member of the beta 1,3‑galactosyl-
transferase family (beta 3GalT6). J Biol Chem 276: 48189–48195. 
Balmer TS, Carels VM, Frisch JL, Nick TA (2009) Modulation of perineuronal 
nets and parvalbumin with developmental song learning. J Neurosci 29: 
12878–12885. 
Bartus K, James ND, Bosch KD, Bradbury EJ (2012) Chondroitin sulphate 
proteoglycans: key modulators of spinal cord and brain plasticity. Exp 
Neurol 235: 5–17. 
Beggah AT, Dours‑Zimmermann MT, Barras FM, Brosius A, Zimmer-
mann  DR, Zurn AD (2005) Lesion‑induced differential expression and 
cell association of Neurocan, Brevican, Versican V1 and V2 in the mouse 
dorsal root entry zone. Neuroscience 133: 749–762. 
Bhattacharyya S, Solakyildirim K, Zhang Z, Linhardt RJ Tobacman JK 
(2009a) Chloroquine reduces arylsulfatase B activity and increases 
chondroitin 4‑sulfate: implications for mechanisms of action and re-
sistance. Malar J 8: 303. 
Bhattacharyya S, Solakyildirim K, Zhang Z, Linhardt RJ, Tobacman JK 
(2009b) Cell‑bound IL‑8 increases in bronchial epithelial cells following 
Arylsulfatase B silencing. Am J Respir Cell Mol Biol 42: 51–61. 
Bhattacharyya S, Zhang X, Feferman L, Johnson D, Tortella FC, Guizzetti M, 
Tobacman JK (2015) Decline in arylsulfatase B and Increase in chondroi-
tin 4‑sulfotransferase combine to increase chondroitin 4‑sulfate in trau-
matic brain injury. J Neurochem 134: 728–739. 
Bracey LT, Paigen K (1987) Changes in translational yield regulate tis-
sue‑specific expression of beta‑glucuronidase. Proc Natl Acad Sci U S 
A 84: 9020–9024. 
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, 
McMahon SB (2002) Chondroitinase ABC promotes functional recovery 
after spinal cord injury. Nature 416: 636–640. 
Brandt AE, Distler J, Jourdian GW (1969) Biosynthesis of the chondroitin 
sulfate‑protein linkage region: purification and properties of a  glucu-
ronosyltransferase from embryonic chick brain. Proc Natl Acad Sci USA 
64: 374–380. 
Carmichael ST, Kathirvelu B, Schweppe CA, Nie EH (2017) Molecular, cellu-
lar and functional events in axonal sprouting after stroke. Exp Neurol 
287: 384–394. 
Carulli D, Rhodes KE, Brown DJ, Bonnert TP, Pollack SJ, Oliver K, Strata P, 
Fawcett JW (2006) Composition of perineuronal nets in the adult rat cer-
ebellum and the cellular origin of their components. J Comp Neurol 494: 
559–577. 
Carulli D, Rhodes KE, Fawcett JW (2007) Upregulation of aggrecan, link pro-
tein 1, and hyaluronan synthases during formation of perineuronal nets 
in the rat cerebellum. J Comp Neurol 501: 83–94. 
Carulli D, Pizzorusso T, Kwok JC, Putignano E, Poli A, Forostyak S, 
Andrews MR, Deepa SS, Glant TT, Fawcett JW (2010) Animals lacking link 
protein have attenuated perineuronal nets and persistent plasticity. 
Brain 133: 2331–2347. 
Celio MR, Blümcke I (1994) Perineuronal nets – a specialized form of ex-
tracellular matrix in the adult nervous system. Brain Res Brain Res Rev 
19: 128–145. 
Condac E, Dale GL, Bender‑Neal D, Ferencz B, Towner R, Hinsdale ME 
(2009) Xylosyltransferase II is a significant contributor of circulating xy-
losyltransferase levels and platelets constitute an important source of 
xylosyltransferase in serum. Glycobiology 19: 829–833. 
348 Gręda and Nowicka Acta Neurobiol Exp 2019, 79: 338–351
Cordeiro P, Hechtman P, Kaplan F (2000) The GM2 gangliosidoses data-
bases: allelic variation at the HEXA, HEXB, and GM2A gene loci. Genet 
Med 2: 319–327. 
Couchman JR, Pataki CA (2012) An introduction to proteoglycans and their 
localization. J Histochem Cytochem 60: 885–897. 
Csoka AB, Scherer SW, Stern R (1999) Expression analysis of six paralo-
gous human hyaluronidase genes clustered on chromosomes 3p21 and 
7q31. Genomics 60: 356–361. 
Csoka AB, Frost GI, Stern R (2001) The six hyaluronidase‑like genes in the 
human and mouse genomes. Matrix Biol 20: 499–508. 
Csoka AB, Stern R (2013) Hypotheses on the evolution of hyaluronan: 
a highly ironic acid. Glycobiology 23: 398–411. 
Deepa SS, Carulli D, Galtrey C, Rhodes K, Fukuda J, Mikami T, Sugahara K, 
Fawcett JW (2006) Composition of perineuronal net extracellular matrix 
in rat brain: a different disaccharide composition for the net‑associated 
proteoglycans. J Biol Chem 281: 17789–17800. 
Egea J, García AG, Verges J, Montell E, López MG (2010) Antioxidant, an-
tiinflammatory and neuroprotective actions of chondroitin sulfate and 
proteoglycans. Osteoarthritis Cartilage 18: S24–27.
Fox K, Caterson B (2002) Neuroscience. Freeing the brain from the peri-
neuronal net. Science 298: 1187–1189. 
Frost GI, Csóka AB, Wong T, Stern R (1997) Purification, cloning and expres-
sion of human plasma hyaluronidase. Biochem Biophys Res Commun 
236: 10–15. 
Fukuta M, Kobayashi Y, Uchimura K, Kimata K, Habuchi O (1998) Molecular 
cloning and expression of human chondroitin 6‑sulfotransferase. Bio-
chim Biophys Acta 1399: 57–61. 
Galtrey CM, and Fawcett JW (2007) The role of chondroitin sulfate proteo-
glycans in regeneration and plasticity in the central nervous system. 
Brain Res Rev 54: 1–18. 
Gary SC, Zerillo CA, Chiang VL, Gaw JU, Gray G, Hockfield S (2000) cDNA 
cloning, chromosomal localization, and expression analysis of human 
BEHAB/brevican, a brain specific proteoglycan regulated during cortical 
development and in glioma. Gene 256: 139–147. 
Giamanco KA, Matthews RT (2012) Deconstructing the perineuronal net: 
cellular contributions and molecular composition of the neuronal extra-
cellular matrix. Neuroscience 218: 367–84.
Gilbert RJ, McKeon RJ, Darr A, Calabro A, Hascall VC, Bellamkonda RV (2005) 
CS‑4,6 is differentially upregulated in glial scar and is a potent inhibitor 
of neurite extension. Mol Cell Neurosci 29: 545–558. 
Glössl J, Truppe W, Kresse H (1979) Purification and properties of N‑acetyl-
galactosamine 6‑sulphate sulphatase from human placenta. Biochem J 
181: 37–46. 
Gogolla N, Caroni P, Lüthi A, Herry C (2009) Perineuronal nets protect fear 
memories from erasure. Science 325: 1258–1261. 
Gotoh M, Sato T, Akashima T, Iwasaki H, Kameyama A, Mochizuki H, Yada T, 
Inaba N, Zhang Y, Kikuchi N, Kwon YD, Togayachi A, Kudo T, Nishihara 
S, Watanabe H, Kimata K, Narimatsu H (2002a) Enzymatic synthesis of 
chondroitin with a  novel chondroitin sulfate N‑acetylgalactosaminyl-
transferase that transfers Nacetylgalactosamine to glucuronic acid in 
initiation and elongation of chondroitin sulfate synthesis. J Biol Chem 
277: 38189–38196. 
Gotoh  M, Yada,T, Sato T, Akashima T, Iwasaki H, Mochizuki H, Inaba N, 
Togayachi A, Kudo T, Watanabe H, Kimata K, Narimatsuet H (2002b) 
Molecular cloning and characterization of a  novel chondroitin sulfate 
glucuronyltransferase that transfers glucuronic acid to N‑acetylgalac-
tosamine. J Biol Chem 277: 38179–38188. 
Götting C, Kuhn J, Zahn R, Brinkmann T, Kleesiek K (2000) Molecular clon-
ing and expression of human UDP‑d‑Xylose: proteoglycan core pro-
tein beta‑d‑xylosyltransferase and its first isoform XT‑II. J Mol Biol 304: 
517–528. 
Gris P, Tighe A, Levin D, Sharma R, Brown A (2007) Transcriptional regula-
tion of scar gene expression in primary astrocytes. Glia 55: 1145–1155. 
Gulberti S, Lattard  V, Fondeur  M, Jacquinet JC, Mulliert G, Netter P, 
Magdalou J, Ouzzine M, Fournel‑Gigleux S (2005) Phosphorylation and 
sulfation of oligosaccharide substrates critically influence the activity 
of human beta1,4‑galactosyltransferase 7 (GalT‑I) and beta1,3‑glucu-
ronosyltransferase I (GlcAT‑I) involved in the biosynthesis of the glycos-
aminoglycan‑protein linkage region of proteoglycans. J Biol Chem 280: 
1417–1425. 
Gulberti S, Jacquinet JC, Chabel M, Ramalanjaona N, Magdalou J, Netter P, 
Coughtrie MW, Ouzzine M, Fournel‑Gigleux S (2012) Chondroitin sulfate 
Nacetylgalactosaminyltransferase‑1 (CSGalNAcT‑1) involved in chon-
droitin sulfate initiation: impact of sulfation on activity and specificity. 
Glycobiology 22: 561–571. 
Gushulak L, Hemming R, Martin D, Seyrantepe V, Pshezhetsky A, Triggs‑
‑Raine B (2012) Hyaluronidase 1 and β‑hexosaminidase have redundant 
functions in hyaluronan and chondroitin sulfate degradation. J  Biol 
Chem 287: 16689–16697. 
Hagen MW, Riddle A, McClendon E, Gong X, Shaver D, Srivastava T, Dean JM, 
Bai JZ, Fowke TM, Gunn AJ, Jones DF, Sherman LS, Grafe MR, Hohimer 
AR, Back SA (2014) Role of recurrent hypoxia‑ischemia in preterm white 
matter injury severity. PLoS ONE 9: e112800. 
Harris NG, Carmichael ST, Hovda DA, Sutton RL (2009) Traumatic brain 
injury results in disparate regions of chondroitin sulfate proteoglycan 
expression that are temporally limited. J Neurosci Res 87: 2937–2950. 
Härtig W, Mages B, Aleithe S, Nitzsche B, Altmann S, Barthel H, Krueger M, 
Michalski D (2017) Damaged neocortical perineuronal nets due to ex-
perimental focal cerebral ischemia in mice, rats and sheep. Front Integr 
Neurosci 11: 15. 
Helting T, Roden L (1969) Biosynthesis of chondroitin sulfate. II. Glucurono-
syl transfer in the formation of the carbohydrate‑protein linkage region. 
J Biol Chem 244: 2799–2805. 
Hiraoka N, Nakagawa H, Ong E, Akama TO, Fukuda MN, Fukuda M (2000) 
Molecular cloning and expression of two distinct human chondroitin 
4‑O‑sulfotransferases that belong to the HNK‑1 sulfotransferase gene 
family. J Biol Chem 275: 20188–20196. 
Hobohm C, Günther A, Grosche J, Rossner S, Schneider D, Brückner G 
(2005) Decomposition and long‑lasting downregulation of extracellular 
matrix in perineuronal nets induced by focal cerebral ischemia in rats. 
J Neurosci Res 80: 539–548. 
Honda T, Kaneiwa T, Mizumoto S, Sugahara K, Yamada S (2012) Hyaluroni-
dases have strong hydrolytic activity toward chondroitin 4‑sulfate com-
parable to that for hyaluronan. Biomolecules 2: 549–563. 
Hou X, Yoshioka N, Tsukano H, Sakai A, Miyata S, Watanabe Y, Yanagawa Y, 
Sakimura K, Takeuchi K, Kitagawa H, Hensch TK, Shibuki K, Igarashi M, 
Sugiyama S (2017) Chondroitin sulfate is required for onset and offset of 
critical period plasticity in visual cortex. Sci Rep 7: 12646. 
Ingmar B, Wasteson A (1979) Sequential degradation of a chondroitin sul-
phate trisaccharide by lysosomal enzymes from embryonic‑chick epiph-
ysial cartilage. Biochem J 179: 7–13. 
Ishii M, Maeda N (2008) Spatiotemporal expression of chondroitin sulfate-
sulfotransferases in the postnatal developing mouse cerebellum. Glyco-
biology 18: 602–614. 
Izumikawa T, Uyama T, Okuura Y, Sugahara K, Kitagawa H (2007) Involve-
ment of chondroitin sulfate synthase‑3 (chondroitin synthase‑2) in 
chondroitin polymerization through its interaction with chondroitin 
synthase‑1 or chondroitinpolymerizing factor. Biochem J 403: 545–552. 
Izumikawa T, Koike T, Shiozawa S, Sugahara K, Tamura J, Kitagawa H (2008) 
Identification of chondroitin sulfate glucuronyltransferase as chondroi-
tin synthase‑3 involved in chondroitin polymerization: chondroitin po-
lymerization is achieved by multiple enzyme complexes consisting of 
chondroitin synthase family members. J Biol Chem 283: 11396–11406. 
Izumikawa T, Okuura Y, Koike T, Sakoda N, Kitagawa H (2011) Chondroitin 
4‑Osulfotransferase‑1 regulates the chain length of chondroitin sulfate 
in co‑operation with chondroitin N‑acetylgalactosaminyltransferase‑2. 
Biochem J 434: 321–331. 
Izumikawa T, Koike T, Kitagawa H (2012) Chondroitin 4‑O‑sulfotransferase‑2 
regulates the number of chondroitin sulfate chains initiated by chondroi-
tin N‑acetylgalactosaminyltransferase‑1. Biochem J 441: 697–705. 
CS synthesis in the brain 349Acta Neurobiol Exp 2019, 79: 338–351
Jaworski DM, Kelly GM, Hockfield S (1994) BEHAB, a new member of the 
proteoglycan tandem repeat family of hyaluronan‑binding proteins that 
is restricted to the brain. J Cell Biol 125: 495–509. 
Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R (2009) Extracellular 
matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 
61: 198–223. 
Jedrzejas MJ, Stern R (2005) Structures of vertebrate hyaluronidases and 
their unique enzymatic mechanism of hydrolysis. Proteins 61: 227–238. 
Jones MH, Davey PM, Aplin H, Affara NA (1995) Expression analysis, ge-
nomic structure, and mapping to 7q31 of the human sperm adhesion 
molecule gene SPAM1. Genomics 29: 796–800. 
Kaneiwa T, Mizumoto S, Sugahara K, Yamada S (2010) Identification of 
human hyaluronidase‑4 as a novel chondroitin sulfate hydrolase that 
preferentially cleaves the galactosaminidic linkage in the trisulfated tet-
rasaccharide sequence. Glycobiology 20: 300–309. 
Kaneiwa T, Miyazaki A, Kogawa R, Mizumoto S, Sugahara K, Yamada S 
(2012) Identification of amino acid residues required for the substrate 
specificity of human and mouse chondroitin sulfate hydrolase (conven-
tional hyaluronidase‑4). J Biol Chem 287: 42119–42128. 
Kang HG, Evers MR, Xia G, Baenziger JU, Schachner  M (2002) Molecular 
cloning and characterization of chondroitin‑4‑O‑sulfotransferase‑3. 
A novel member of the HNK‑1 family of sulfotransferases. J Biol Chem 
277: 34766–34772. 
Karetko‑Sysa M, Skangiel‑Kramska J, Nowicka D (2011) Disturbance of peri-
neuronal nets in the perilesional area after photothrombosis is not as-
sociated with neuronal death. Exp Neurol 231: 113–126. 
Keino H, Sato H, Kashiwamata S (1990) Distribution of acid phospha-
tase and beta‑glucuronidase in the hypoplastic cerebellum of jaun-
diced Gunn rats. An enzyme histochemical study. Cell Tissue Res 262: 
515–517. 
Kitagawa H, Tone Y, Tamura J, Neumann KW, Ogawa T, Oka S, Kawasaki T, 
Sugahara K (1998) Molecular cloning and expression of glucuronyltrans-
ferase I involved in the biosynthesis of the glycosaminoglycan‑protein 
linkage region of proteoglycans. J Biol Chem 273: 6615–6618. 
Kitagawa H, Fujita M, Ito N, Sugahara K (2000) Molecular cloning and ex-
pression of a novel chondroitin 6‑O‑sulfotransferase. J Biol Chem 275: 
21075–21080. 
Kitagawa H, Taoka M, Tone Y, Sugahara K (2001a) Human glycosaminogly-
can glucuronyltransferase I gene and a related processed pseudogene: 
genomic structure, chromosomal mapping and characterization. Bio-
chem J 358: 539–546. 
Kitagawa H, Uyama T, Sugahara K (2001b) Molecular cloning and expres-
sion of a human chondroitin synthase, J Biol Chem 276: 38721–38726. 
Kitagawa H, Izumikawa T, Uyama T, Sugahara K (2003) Molecular cloningof 
a chondroitin polymerizing factor that cooperates with chondroitin syn-
thase for chondroitin polymerization. J Biol Chem 278: 23666–23671. 
Kitagawa H, Tsutsumi K, Ikegami‑Kuzuhara A, Nadanaka S, Goto F, 
Ogawa T, Sugahara K (2008) Sulfation of the galactose residues in the 
glycosaminoglycan protein linkage region by recombinant human chon-
droitin 6‑O‑sulfotransferase‑1. J Biol Chem 283: 27438–27443. 
Kleene R, Schachner M (2004) Glycans and neural cell interactions. Nat Rev 
Neurosci 5: 195–208. 
Kobayashi M, Sugumaran G, Liu J, Shworak NW, Silbert JE, Rosenberg RD 
(1999) Molecular cloning and characterization of a human uronyl 2‑sul-
fotransferase that sulfates iduronyl and glucuronyl residues in der-
matan/chondroitin sulfate. J Biol Chem 274: 10474–10480. 
Kobayashi T, Yan H, Kurahashi Y, Ito Y, Maeda H, Tada T, Hongo K, 
Nakayama J (2013) Role of GalNAc4S‑6ST in astrocytic tumor progres-
sion. PLoS One 8: e54278. 
Koike T, Izumikawa T, Tamura J, Kitagawa H (2009) FAM20B is a kinase that 
phosphorylates xylose in the glycosaminoglycan‑protein linkage region. 
Biochem 421: 157–162. 
Koike T, Izumikawa T, Sato B, Kitagawa H (2014) Identification of phospha-
tase that dephosphorylates xylose in the glycosaminoglycan‑protein 
linkage region of proteoglycans. J Biol Chem 289: 6695–6708.
Kroh H, Renkawek K (1973) Cytochemical distribution of beta‑glucuroni-
dase activity in experimental brain tumors and brain tissue in vivo and 
in vitro. Histochemie 34: 317–324. 
Kusche‑Gullberg M, Kjellén L (2003) Sulfotransferases in glycosaminogly-
can biosynthesis. Curr Opin Struct Biol 13: 605–611. 
Laabs TL, Wang H, Katagiri Y, McCann T, Fawcett JW, Geller HM (2007) Inhib-
iting glycosaminoglycan chain polymerization decreases the inhibitory 
activity of astrocyte‑derived chondroitin sulfate proteoglycans. J Neuro-
sci 27: 14494–14501. 
Lin Y, Kimmel LH, Myles DG, Primakoff P (1993) Molecular cloning of the 
human and monkey sperm surface protein PH‑20. Proc Natl Acad Sci U 
S A 90: 10071–10075. 
Lin R, Rosahl TW, Whiting PJ, Fawcett JW, Kwok JCF (2011) 6‑Sulphated 
chondroitins have a  positive influence on axonal regeneration. PLoS 
ONE 6: e21499. 
Lindwall C, Olsson M, Osman AM, Kuhn HG, Curtis MA (2013) Selective ex-
pression of hyaluronan and receptor for hyaluronan mediated motility 
(Rhamm) in the adult mouse subventricular zone and rostral migratory 
stream and in ischemic cortex. Brain Res 1503: 62–77. 
Lohmander LS, Hascall VC, Yanagishita M, Kuettner KE, Kimura JH (1986) 
Post translational events in proteoglycan synthesis: kinetics of synthesis 
of chondroitin sulfate and oligosaccharides on the core protein. Arch 
Biochem Biophys 250: 211–227. 
Maeda N (2010) Structural variation of chondroitin sulfate and its roles 
in the central nervous system. Cent Nerv Syst Agents Med Chem 10: 
22–31. 
Marella  M, Ouyang J, Zombeck J, Zhao C, Huang  L, Connor RJ, Phan KB, 
Jorge MC, Printz MA, Paladini RD, Gelb AB, Huang Z, Frost GI, Sugarman 
BJ, Steinman  L, Wei G, Shepard HM, Maneval DC, Lapinskas PJ (2017) 
PH20 is not expressed in murine CNS and oligodendrocyte precursor 
cells. Ann Clin Transl Neurol 4: 191–211. 
Maurel P, Rauch U, Flad M, Margolis RK, Margolis RU (1994) Phosphacan, 
a chondroitin sulfate proteoglycan of brain that interacts with neurons 
and neural cell‑adhesion molecules, is an extracellular variant of a re-
ceptor‑type protein tyrosine phosphatase. Proc Natl Acad Sci U S A 91: 
2512–2516.
Matthews RT, Kelly GM, Zerillo CA, Gray G, Tiemeyer M, Hockfield S (2002) 
Aggrecan glycoforms contribute to the molecular heterogeneity of peri-
neuronal nets. J Neurosci 22: 7536–7547. 
Mazany KD, Peng T, Watson CE, Tabas I, Williams KJ (1998) Human chon-
droitin 6‑sulfotransferase: cloning, gene structure, and chromosomal 
localization. Biochim Biophys Acta 1407: 92–97. 
McKeon RJ, Jurynec MJ, Buck CR (1999) The chondroitin sulfate proteogly-
cans neurocan and phosphacan are expressed by reactive astrocytes in 
the chronic CNS glial scar. J Neurosci 19: 10778–10788. 
McRae PA, Baranov E, Rogers SL, Porter BE (2012) Persistent decrease in 
multiple components of the perineuronal net following status epilepti-
cus. Eur J Neurosci 36: 3471–3482. 
Midura RJ, Calabro A, Yanagishita M, Hascall VC (1995) Nonreducing end 
structures of chondroitin sulfate chains on aggrecan isolated from 
Swarm rat chondrosarcoma cultures. J Biol Chem 270: 8009–8015. 
Mikami T, Kitagawa H (2013) Biosynthesis and function of chondroitin sul-
fate. Biochim Biophys Acta 1830: 4719–4733. 
Milev P, Maurel P, Chiba A, Mevissen  M, Popp S, Yamaguchi Y, 
Margolis RK, Margolis RU (1998) Differential regulation of expression 
of hyaluronan‑binding proteoglycans in developing brain: aggrecan, 
versican, neurocan, and brevican. Biochem Biophys Res Commun 
247: 207–212. 
Mitsunaga‑Nakatsubo K, Kusunoki S, Kawakami H, Akasaka K, Akimoto Y 
(2009) Cell‑surface arylsulfatase A and B on sinusoidal endothelial cells, 
hepatocytes, and Kupffer cells in mammalian livers. Med Mol Morphol 
42: 63–69. 
Miyata S, Nishimura Y, Nakashima T (2007) Perineuronal nets protect 
against amyloid beta‑protein neurotoxicity in cultured cortical neurons. 
Brain Res 1150: 200–206. 
350 Gręda and Nowicka Acta Neurobiol Exp 2019, 79: 338–351
Miyata S, Komatsu Y, Yoshimura Y, Taya C, Kitagawa H (2012) Persistent 
cortical plasticity by upregulation of chondroitin 6‑sulfation. Nat Neu-
rosci 15: 414–422. 
Miyata S, Kitagawa H (2017) Formation and remodeling of the brain ex-
tracellular matrix in neural plasticity: Roles of chondroitin sulfate and 
hyaluronan. Biochim Biophys Acta Gen Subj 1861: 2420–2434. 
Miyata S, Nadanaka S, Igarashi M, Kitagawa H (2018) Structural variation of 
chondroitin sulfate chains contributes to the molecular heterogeneity 
of perineuronal nets. Front Integr Neurosci 12: 3. 
Morawski M, Brückner MK, Riederer P, Brückner G, Arendt T (2004) Peri-
neuronal nets potentially protect against oxidative stress. Exp Neurol 
188: 309–315. 
Morawski  M, Pavlica S, Seeger G, Grosche J, Kouznetsova E, Schliebs R, 
Brückner G, Arendt T (2010) Perineuronal nets are largely unaffected in 
Alzheimer model Tg2576 mice. Neurobiol Aging 31: 1254–1256. 
Morawski M, Brückner G, Jäger C, Seeger G, Matthews RT, Arendt T (2012) 
Involvement of perineuronal and perisynaptic extracellular matrix in 
Alzheimer’s disease neuropathology. Brain Pathol 22: 547–561. 
Motas S, Haurigot  V, Garcia  M, Marcó S, Ribera A, Roca C, Sánchez X, 
Sánchez V, Molas M, Bertolin J, Maggioni L, León X, Ruberte J, Bosch F 
(2016) CNS‑directed gene therapy for the treatment of neurologic and 
somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight 
1: e86696. 
Nikolovska K, Spillmann D, Seidler DG (2015) Uronyl 2‑O sulfotransferase 
potentiates Fgf2‑induced cell migration. J Cell Sci 128: 460–471. 
Ogawa H, Shionyu M, Sugiura N, Hatano S, Nagai N, Kubota Y, Nishiwaki K, 
Sato T, Gotoh M, Narimatsu H, Shimizu K, Kimata K, Watanabe H (2010) 
Chondroitin sulfate synthase‑2/chondroitin polymerizing factor has two 
variants with distinct function. J Biol Chem 285: 34155–34167. 
Ohtake S, Ito Y, Fukuta  M, Habuchi O (2001) Human N‑acetylgalac-
tosamine 4‑sulfate 6‑O‑sulfotransferase cDNA is related to human B 
cell recombination activating gene‑associated gene. J Biol Chem 276: 
43894–43900. 
Ohtake‑Niimi S, Kondo S, Ito T, Kakehi S, Ohta T, Habuchi H, Kimata K, 
Habuchi O (2010) Mice deficient in N‑acetylgalactosamine 4‑sulfate 
6‑o‑sulfotransferase are unable to synthesize chondroitin/dermatan 
sulfate containing N‑acetylgalactosamine 4,6‑bissulfate residues and 
exhibit decreased protease activity in bone marrow derived mast cells. 
J Biol Chem 285: 20793–20805. 
Okuda H, Tatsumi K, Horii‑Hayashi N, Morita S, Okuda‑Yamamoto A, 
Imaizumi K, Wanaka A (2014) OASIS regulates chondroitin 6‑O‑sulfo-
transferase 1 gene transcription in the injured adult mouse cerebral 
cortex. J Neurochem 130: 612–625. 
Oegema TRJ, Kraft EL, Jourdian GW, Van Valen TR (1984) Phosphorylation 
of chondroitin sulfate in proteoglycans from the Swarm rat chondrosar-
coma. J Biol Chem 259: 1720–1726. 
Pizzorusso T, Medini P, Berardi N (2002) Reactivation of ocular dominance 
plasticity in the adult visual cortex. Science 298: 1248–1251. 
Pizzorusso T, Medini P, Landi S, Baldini S, Berardi N, Maffei L (2006) Struc-
tural and functional recovery from early monocular deprivation in adult 
rats. Proc Natl Acad Sci U S A 103: 8517–8522.
Pönighaus C, Ambrosius  M, Casanova JC, Prante C, Kuhn J, Esko JD, 
Kleesiek K, Götting C (2007) Human xylosyltransferase II is involved in 
the biosynthesis of the uniform tetrasaccharide linkage region in chon-
droitin sulfate and heparan sulfate proteoglycans. J  Biol Chem 282: 
5201–5206. 
Prabhakar  V, Sasisekharan R (2006) The biosynthesis and catabolism of 
galactosaminoglycans. Adv Pharmacol 53: 69–115. 
Prabhu S, Bhattacharyya S, Guzman G, Macias  V, Kajdacsy‑Balla A, 
Tobacman JK (2011) Extra‑lysosomal localization of arylsulfatase B in 
human colonic epithelium. J Histochem Cytochem 59: 328–335. 
Preston M, Gong X, Su W, Matsumoto SG, Banine F, Winkler C, Foster S, 
Xing R, Struve J, Dean J, Baggenstoss B, Weigel PH, Montine TJ, Back SA, 
Sherman LS (2013) Digestion products of the PH20 hyaluronidase inhib-
it remyelination. Ann Neurol 73: 266–280. 
Properzi F, Carulli D, Asher RA, Muir E, Camargo LM, van Kuppevelt TH, 
ten  Dam GB, Furukawa Y, Mikami T, Sugahara K, Toida T, Geller HM, 
Fawcett JW (2005) Chondroitin 6‑sulphate synthesis is up‑regulated in 
injured CNS, induced by injury‑related cytokines and enhanced in ax-
on‑growth inhibitory glia. Eur J Neurosci 21: 378–390. 
Rauch U, Gao P, Janetzko A, Flaccus A, Hilgenberg L, Tekotte H, Margolis 
RK, Margolis RU (1991) Isolation and characterization of developmen-
tally regulated chondroitin sulfate and chondroitin/keratan sulfate pro-
teoglycans of brain identified with monoclonal antibodies. J Biol Chem 
266: 14785–14801.
Rauch U, Karthikeyan L, Maurel P, Margolis RU, Margolis RK (1992) Clon-
ing and primary structure of neurocan, a  developmentally regulated, 
aggregating chondroitin sulfate proteoglycan of brain. J Biol Chem 267: 
19536–19547.
Robins E, Hirsch HE, Emmons SS (1968) Glycosidases in the nervous sys-
tem. I. Assay, some properties, and distribution of beta‑galactosidase, 
beta‑glucoronidase, and beta‑glucosidase. J Biol Chem 243: 4246–4252. 
Sakai A, Nakato R, Ling YW, Hou XB, Hara N, Iijima T, Yanagawa Y, Kuwano R, 
Okuda S, Shirahige K, Sugiyama S (2017) Genome‑Wide target analyses 
of otx2 homeoprotein in postnatal cortex. Front Neurosci 11: 307. 
Sato T, Gotoh  M, Kiyohara K, Akashima T, Iwasaki H, Kameyama  A, 
Mochizuki H, Yada T, Inaba N, Togayachi A, Kudo T, Asada  M, 
Watanabe H, Imamura T, Kimata K, Narimatsu H (2003) Differential roles 
of two N‑acetylgalactosaminyltransferases, CSGalNAcT‑1, and a  novel 
enzyme, CSGalNAcT‑2. Initiation and elongation in synthesis of chon-
droitin sulfate. J Biol Chem 278: 3063–3071. 
Shuttleworth TL, Wilson MD, Wicklow BA, Wilkins JA, Triggs‑Raine BL 
(2002) Characterization of the murine hyaluronidase gene region re-
veals complex organization and cotranscription of Hyal1 with down-
stream genes, Fus2 and Hyal3 J Biol Chem 277: 23008–23018. 
Silbert JE, Sugumaran G (2002) Biosynthesis of chondroitin/dermatan sul-
fate. IUBMB Life 54: 177–186. 
Siebert JR, Conta Steencken A, Osterhout DJ (2014) Chondroitin sulfate pro-
teoglycans in the nervous system: inhibitors to repair. Biomed Res Int 
2014: 845323. 
Slaker  M, Churchill  L, Todd RD, Blacktop JM, Zuloaga DG, Raber J, 
Darling RA, Brown TE, Sorg BA (2015) Removal of perineuronal nets in 
the medial prefrontal cortex impairs the acquisition and reconsolidation 
of a cocaine‑induced conditioned place preference memory. J Neurosci 
35: 4190–4202. 
Sloane JA, Batt C,Ma Y, Harris ZM, Trapp B, Vartanian T (2010) Hyaluro-
nan blocks oligodendrocyte progenitor maturation and remyelination 
through TLR2. Proc Natl Acad Sci U S A 107: 11555–11560. 
Snow DM, Lemmon V, Carrino DA, Caplan AI, Silver J (1990) Sulfated pro-
teoglycans in astroglial barriers inhibit neurite outgrowth in vitro. Exp 
Neurol 109: 111–130. 
Sugahara K, Kitagawa H (2000) Recent advances in the study of the biosyn-
thesis and functions of sulfated glycosaminoglycans. Curr Opin Struct 
Biol 10: 518–527. 
Sugahara K, Mikami T (2007) Chondroitin/dermatan sulfate in the central 
nervous system. Curr Opin Struct Biol 17: 536–545. 
Sugiyama S, Di Nardo AA, Aizawa S, Matsuo I, Volovitch M, Prochiantz A, 
Hensch TK (2008) Experience‑dependent transfer of Otx2 homeoprotein 
into the visual cortex activates postnatal plasticity. Cell 134: 508–520. 
Suttkus A, Rohn S, Jäger C, Arendt T, Morawski M (2012) Neuroprotection 
against iron‑induced cell death by perineuronal nets ‑ an in vivo analysis 
of oxidative stress. Am J Neurodegener Dis 1: 122–129. 
Suttkus A, Holzer  M, Morawski  M, Arendt T (2016) The neuronal extra-
cellular matrix restricts distribution and internalization of aggregated 
Tau‑protein. Neuroscience 313: 225–235. 
Sykova E, Nicholson C (2008) Diffusion in brain extracellular space. Physiol 
Rev 88: 1277–1340. 
Tachi Y, Okuda T, Kawahara N, Kato N, Ishigaki Y, Matsumoto T (2015) 
Expression of hyaluronidase‑4 in a rat spinal cord hemisection model. 
Asian Spine J 9: 7–13. 
CS synthesis in the brain 351Acta Neurobiol Exp 2019, 79: 338–351
Tao J, Liu W, Shang G, Zheng Y, Huang J, Lin R, Chen L (2015) MiR‑207/352 
regulate lysosomal‑associated membrane proteins and enzymes fol-
lowing ischemic stroke. Neuroscience 305: 1–14. 
Tone Y, Pedersen LC, Yamamoto T, Izumikawa T, Kitagawa H, Nishihara J, 
Tamura J, Negishi M, Sugahara K (2008) 2‑o‑phosphorylation of xylose 
and 6‑osulfation of galactose in the protein linkage region of glycosami-
noglycans influence the glucuronyltransferase‑I activity involved in the 
linkage region synthesis. J Biol Chem 283: 16801–16807. 
Tropea D, Caleo  M, Maffei  L (2003) Synergistic effects of brain‑derived 
neurotrophic factor and chondroitinase ABC on retinal fiber sprouting 
after denervation of the superior colliculus in adult rats. J Neurosci 23: 
7034–7044. 
Uchimura K, Muramatsu H, Kadomatsu K, Fan QW, Kurosawa N, 
Mitsuoka C, Kannagi R, Habuchi O, Muramatsu T (1998) Molecular clon-
ing and characterization of an N‑acetylglucosamine‑6‑O‑sulfotransfer-
ase. J Biol Chem 273: 22577–22583. 
Uchimura K, Kadomatsu K, Nishimura H, Muramatsu H, Nakamura E, 
Kurosawa N, Habuchi O, El‑Fasakhany FM, Yoshikai Y, Muramatsu T 
(2002) Functional analysis of the chondroitin 6‑sulfotransferase gene in 
relation to lymphocyte subpopulations, brain development, and over-
sulfated chondroitin sulfates. J Biol Chem J 277: 1443–1450. 
Uyama T, Kitagawa H, Tamura Ji J, Sugahara K (2002) Molecular cloning 
and expression of human chondroitin N‑acetylgalactosaminyltransfer-
ase: the key enzyme for chain initiation and elongation of chondroitin/
dermatan sulfate on the protein linkage region tetrasaccharide shared 
by heparin/heparan sulfate. J Biol Chem 277: 8841–8846. 
Uyama T, Kitagawa H, Tanaka J, Tamura J, Ogawa T, Sugahara K (2003) Mo-
lecular cloning and expression of a second chondroitin N‑acetylgalac-
tosaminyltransferase involved in the initiation and elongation of chon-
droitin/dermatan sulfate. J Biol Chem 278: 3072–3078. 
Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu ZX, Tan F, 
Santiago L, Mills EM, Wang Y, Symes AJ, Geller HM (2008) Chondroitin‑4‑ 
sulfation negatively regulates axonal guidance and growth. J Cell Sci 121: 
3083–3091. 
Wakamatsu N, Benoit G, Lamhonwah AM, Zhang ZX, Trasler JM, Triggs‑
‑Raine BL, Gravel RA (1994) Structural organization, sequence, and 
expression of the mouse HEXA gene encoding the alpha subunit of 
hexosaminidase A. Genomics 24: 110–119. 
Wei G, Bai X, Sarkar AK, Esko JD (1999) Formation of HNK‑1 determinants 
and the glycosaminoglycan tetrasaccharide linkage region by UDP‑Gl-
cUA: Galactose beta1, 3 glucuronosyltransferases. J  Biol Chem 274: 
7857–7864. 
Vijayan VK, Cotman CW (1983) Lysosomal enzyme changes in young 
and aged control and entorhinal‑lesioned rats. Neurobiol Aging 4: 
13–23. 
Xing G, Ren M, Verma A (2014) Divergent temporal expression of hyaluronan 
metabolizing enzymes and receptors with craniotomy vs. controlled‑corti-
cal impact injury in rat brain: A pilot study. Front Neurol 5: 173. 
Yada T, Sato T, Kaseyama H, Gotoh  M, Iwasaki H, Kikuchi N, Kwon YD, 
Togayachi A, Kudo T, Watanabe H, Narimatsu H, Kimata K (2003) Chon-
droitin sulfate synthase‑3. Molecular cloning and characterization. J Biol 
Chem 278: 39711–39725. 
Yamaguchi Y (2000) Lecticans: organizers of the brain extracellular matrix. 
Cell Mol Life Sci 57 : 276–289. 
Yamauchi S, Hirahara Y, Usui H, Takeda Y, Hoshino M, Fukuta M, Kimura JH, 
Habuchi O (1999) Purification and characterization of chondroitin 4‑sul-
fotransferase from the culture medium of a  rat chondrosarcoma cell 
line. J Biol Chem 274: 2456–2463. 
Yamauchi S, Mita S, Matsubara T, Fukuta M, Habuchi H, Kimata K, Habuchi O 
(2000) Molecular cloning and expression of chondroitin 4‑sulfotransfer-
ase. J Biol Chem 275: 8975–8981. 
Yamauchi S, Kurosu A, Hitosugi M, Nagai T, Oohira A, Tokudome S (2011) 
Differential gene expression of multiple chondroitin sulfate modifica-
tion enzymes among neural stem cells, neurons and astrocytes. Neuro-
sci Lett 493: 107–111. 
Yang S, Hilton S, Alves JN, Saksida LM, Bussey T, Matthews RT, Kitagawa H, 
Spillantini MG, Kwok JCF, Fawcett JW (2017) Antibody recognizing 4‑sul-
fated chondroitin sulfate proteoglycans restores memory in tauopa-
thy‑induced neurodegeneration. Neurobiol Aging 59: 197–209. 
Yi JH, Katagiri Y, Susarla B, Figge D, Symes AJ, Geller HM (2012) Alterations 
in sulfated chondroitin glycosaminoglycans following controlled cortical 
impact injury in mice. J Comp Neurol 520: 3295–3313. 
Yin J, Sakamoto K, Zhang H, Ito Z, Imagama S, Kishida S, Natori T, Sawada M, 
Matsuyama Y, Kadomatsu K (2009) Transforming growth factor‑beta1 
upregulates keratan sulfate and chondroitin sulfate biosynthesis in mi-
croglias after brain injury. Brain Res 1263: 10–22. 
Zhang X, Bhattacharyya S, Kusumo H, Goodlett CR, Tobacman JK, 
Guizzetti  M (2014) Arylsulfatase B modulates neurite outgrowth via 
astrocyte chondroitin‑4‑sulfate: dysregulation by ethanol. Glia 62: 
259–271. 
Zhou D, Dinter A, Gutierrez Gallego R, Kamerling JP, Vliegenthart JF, 
Berger  EG, Hennet T (1999) A ß1,3‑N‑acetylglucosaminyltransferase 
with poly‑N‑acetyllactosamine synthase activity is structurally related to 
ß1,3‑galactosyltransferases. Proc Natl Acad Sci USA 96: 406–411. 
